ClinicalTrials.gg
CompletedNCT06262425Updated Sep 2, 2025

rTMS Over S1 Enhance Motor Learning in Healthy People

An interventional study of repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex and repetitive Transcranial Magnetic Stimulation over primary motor cortex in Transcranial Magnetic Stimulation and Motor Learning, sponsored by Neuron, Spain. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Neuron, Spain · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to compare the effectiveness of different repetitive Transcranial Magnetic Stimulation protocols for enhancing motor learning in healthy peolple.

Read the detailed description

This randomized clinical trial aims to compare the effectiveness of different repetitive Transcranial Magnetic Stimulation (rTMS) protocols in enhancing motor learning in healthy individuals. It focuses on two key brain areas: the primary motor cortex (M1) and the primary somatosensory cortex (S1), recognized for their roles in motor skill acquisition and execution.

Motor learning involves two distinct neural networks: the associative/premotor and sensorimotor networks. Studies suggest that the associative/premotor network predominates initially, followed by the sensorimotor network. M1 stores movement patterns, whereas S1 appears crucial for initial motor learning and movement adaptation.

rTMS, a non-invasive technique modulating neuronal excitability, has been used to improve motor function in patients with brain injuries. However, its effectiveness in healthy individuals has been variable, especially when stimulating M1 and S1. Prior research suggests that inhibitory rTMS in S1 may influence motor learning, but findings regarding its excitatory effect and comparison with M1 stimulation are mixed.

The primary hypothesis posits that excitatory rTMS in S1 will yield superior motor learning improvements compared to M1 stimulation in healthy individuals. The secondary hypothesis predicts improvements independent of the stimulated area.

The study will involve healthy participants, utilizing tests for accuracy and time. Methodology includes randomization, blind evaluation, and rTMS application based on assigned groups.

With a sample size of 35 subjects per group, data will be analyzed using parametric and non-parametric statistical tests to compare the effects of rTMS on M1 and S1 concerning motor learning in healthy subjects. Results will be considered significant with p \< 0.05, and effect size will be evaluated.

This trial aims to provide clarity on the effectiveness of excitatory rTMS in specific brain areas to enhance motor learning in individuals without neurological pathologies, potentially impacting rehabilitation and motor performance.

02

Conditions studied

  • Transcranial Magnetic Stimulation
  • Motor Learning

Keywords

  • Transcranial magnetic stimulation
  • Motor learning
  • Somatosensory cortex
  • Motor function
03

In context

Lead sponsor

Neuron, Spain is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older than 18 years old and younger than 65

Exclusion criteria

Exclusion Criteria:

  • Presenting any neurological pathology
  • Pain during the study
  • Any to rTMS, such as metal implants, history of epileptic seizures or taking medication that lowers the seizure threshold
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex

    Participants in the experimental group will receive 5 weekly sessions of repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks. An excitatory stimulation over the primary somatosensory area corresponding to the dominant hand will be applied. For this purpose, the motor area will be localized and a coil will be placed 2 cm posterior to it. An isolated pulse will be applied to the motor area to ensure that the coil is not placed over the motor area using 110% of the motor resting threshold. After this, 22 trains of 10 Hz at an intensity of 90% of the motor resting threshold will be applied for 4 seconds, with a rest between series of 10 seconds (a total of 880 pulses). After the stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.

    Device: repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex

  • Active comparator
    repetitive Transcranial Magnetic Stimulation over primary motor cortex

    Participants in the active comparator group will receive 5 weekly sessions of repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks. An excitatory stimulation over the primary motor cortex corresponding to the dominant hand will be applied. For this purpose, the motor area will be localized, and an isolated pulse will be applied to the motor area to ensure that the coil is placed over the motor area using 100% of the motor resting threshold. After this, 22 trains of 10 Hz at an intensity of 90% of the motor resting threshold will be applied for 4 seconds, with a rest between series of 10 seconds (a total of 880 pulses). After the stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.

    Device: repetitive Transcranial Magnetic Stimulation over primary motor cortex

  • Sham comparator
    Sham repetitive transcranial magnetic stimulation

    Participants in the sham group will receive 5 weekly sessions of sham repetitive Transcranial Magnetic Stimulation (rTMS) for two weeks.To achieve the placebo, the localization of the area to be stimulated will be carried out but the coil will be placed in a vertical position so the current will not go through the skull and the patient will just feel the vibration, communicating to the participant that it is likely that during the stimulation process he/she will not feel anything. After the sham stimulation, participants will train with the Forced Response training program for a total of 500 correct repetitions and the Purdue Pegboard Test with 4 repetitions for right hand, left hand and both hands.

    Device: sham repetitive Transcranial Magnetic Stimulation

Interventions

  • Devicerepetitive Transcranial Magnetic Stimulation over primary somatosensory cortex

    It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning

  • Devicerepetitive Transcranial Magnetic Stimulation over primary motor cortex

    It will be applyed a magnetic field over the primary motor cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning

  • Devicesham repetitive Transcranial Magnetic Stimulation

    It will be applied a sham stimulation with the same protocol that pretends to create the illusion of being stimulated

06

What researchers measure

Primary outcomes

  1. Change in accuracy

    Accuracy in associating one letter of the keyboard with a letter from the Phoenician alphabet presented in the screen. It will be measured by using the software PsychoPy, that has been used in other studies for measuring motor learning in an indirect way.

    Time frame: Change from Baseline to 5 days and 10 days in accuracy

Secondary outcomes

  1. Change in reaction time speed

    Reaction time for responding correctly the association between one letter of the keyboard and a letter from the Phoenician alphabet presented in the screen. It will be measured by using the software PsychoPy, that has been used in other studies for measuring motor learning in an indirect way.

    Time frame: Change from Baseline to 5 days and 10 days in reaction time speed

  2. Change in pegs placed in 30 seconds

    Number of pegs placed in a pegboard in 30 seconds will be measured. Patients will use just right hand first, after they will use just their left hand and finally with both hand at same time. This procedure will be repeated and average pegs placed in each condition will be noted. Purdue Pegboard Test will be used for measuring.

    Time frame: Change from Baseline to 5 days and 10 days in days placed in 30 seconds

07

Study locations

1 site
  • Neuron
    Madrid, Madrid 28045, Spain
08

References and documents

Publications

  • Lerin-Calvo A, Moreno-Verdu M, Remon-Ramiro L, Hardwick RM, Lasheras-Cuerda C, Lerma-Lara S, Ferrer-Pena R. Effects of Different Repetitive Transcranial Magnetic Stimulation Targets for Enhancing Motor Learning: A Single-Blind Randomized Controlled Trial. Neural Plast. 2026;2026(1):e6487874. doi: 10.1155/np/6487874. PubMed 42241053 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jul 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Feb 16, 2024
StartActual
Jan 20, 2024
Primary completionActual
Jul 15, 2025
CompletionActual
Jul 15, 2025
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06262425
Lead sponsor
Neuron, Spain
Responsible party
Sponsor
First posted
Feb 16, 2024
Start date
Jan 20, 2024
Primary completion
Jul 15, 2025
Completion
Jul 15, 2025
Last update
Sep 2, 2025

Study contacts

Alfredo Lerín Calvo, PhD student
principal investigator · Neuron, Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion